Tissue Regenix Group PLC Company Profile (LON:TRX)

About Tissue Regenix Group PLC (LON:TRX)

Tissue Regenix Group PLC logoTissue Regenix Group plc is a medical technology company. The Company is engaged in the development of regenerative products to make replacement native tissue using biological (human and animal) tissues. It operates through Cardiac, Wound Care and Orthopaedics divisions. Its decellularisation (dCELL) technology removes deoxyribonucleic acid and other cellular material from tissue leaving an acellular scaffold, which is not rejected by the patient's body. The dCELL has applications in wound care, heart valve replacement and knee repair. Its products portfolio includes DermaPure, which is used for the treatment of chronic or acute wounds; SurgiPure XD Surgical Tissue Matrix, which is used as a soft tissue patch for the surgical repair of damaged or ruptured soft tissue membranes; OrthoPure XM, which is used to replace the tissue removed during a partial meniscopy; OrthoPure XT, which is a decellurised porcine tendon, and CardioPure, a decellurised human pulmonary or aortic heart valve.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: LON:TRX
  • CUSIP: N/A
  • Web: N/A
Capitalization:
  • Market Cap: £111.48 million
  • Outstanding Shares: 743,183,000
Average Prices:
  • 50 Day Moving Avg: GBX 15.51
  • 200 Day Moving Avg: GBX 17.73
  • 52 Week Range: GBX 14 - GBX 22
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: £1.2 million
  • Price / Sales: 92.90
  • Book Value: GBX 0.02 per share
  • Price / Book: 7.50
Profitability:
  • EBIDTA: ($11,350,000.00)
Misc:
  • Average Volume: 113,912 shs.
 

Frequently Asked Questions for Tissue Regenix Group PLC (LON:TRX)

What is Tissue Regenix Group PLC's stock symbol?

Tissue Regenix Group PLC trades on the London Stock Exchange (LON) under the ticker symbol "TRX."

Where is Tissue Regenix Group PLC's stock going? Where will Tissue Regenix Group PLC's stock price be in 2017?

2 equities research analysts have issued 1-year target prices for Tissue Regenix Group PLC's stock. Their forecasts range from GBX 39 to GBX 39. On average, they expect Tissue Regenix Group PLC's share price to reach GBX 39 in the next year. View Analyst Ratings for Tissue Regenix Group PLC.

Who are some of Tissue Regenix Group PLC's key competitors?

Who are Tissue Regenix Group PLC's key executives?

Tissue Regenix Group PLC's management team includes the folowing people:

  • John Samuel, Executive Chairman of the Board

How do I buy Tissue Regenix Group PLC stock?

Shares of Tissue Regenix Group PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Tissue Regenix Group PLC's stock price today?

One share of Tissue Regenix Group PLC stock can currently be purchased for approximately GBX 15.


MarketBeat Community Rating for Tissue Regenix Group PLC (LON TRX)
Community Ranking:  3.5 out of 5 (   )
Outperform Votes:  57 (Vote Outperform)
Underperform Votes:  24 (Vote Underperform)
Total Votes:  81
MarketBeat's community ratings are surveys of what our community members think about Tissue Regenix Group PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Tissue Regenix Group PLC (LON:TRX) (?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: GBX 39

Analysts' Ratings History for Tissue Regenix Group PLC (LON:TRX)
Show:
DateFirmActionRatingPrice TargetDetails
12/7/2016Jefferies Group LLCLower Price TargetBuyGBX 40 -> GBX 39View Rating Details
10/13/2016Beaufort SecuritiesReiterated RatingSpeculative BuyView Rating Details
(Data available from 5/29/2015 forward)

Earnings

Earnings History for Tissue Regenix Group PLC (LON:TRX)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Tissue Regenix Group PLC (LON:TRX)
Current Year EPS Consensus Estimate: $-1.47 EPS

Dividends

Dividend History for Tissue Regenix Group PLC (LON:TRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Tissue Regenix Group PLC (LON:TRX)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Tissue Regenix Group PLC (LON:TRX)
Latest Headlines for Tissue Regenix Group PLC (LON:TRX)
Source:
DateHeadline
morningstar.co.uk logoTissue Regenix In Talks To Buy US Regenerative Medicine Firm CellRight
www.morningstar.co.uk - May 19 at 1:18 PM
morningstar.co.uk logoTissue Regenix's DermaPure Gets Contract In US With Vizient
www.morningstar.co.uk - March 2 at 9:00 AM
morningstar.co.uk logoTissue Regenix Hires Paul Devlin As New Finance Director
www.morningstar.co.uk - January 6 at 6:16 AM
uk.finance.yahoo.com logoIs this stock a buy after reporting a 150% increase in revenue?
uk.finance.yahoo.com - October 12 at 10:55 AM
uk.finance.yahoo.com logoTissue Regenix Group plc: DermaPure® - Two Peer Reviewed Clinical Papers Published
uk.finance.yahoo.com - September 15 at 11:31 AM
uk.finance.yahoo.com logoTissue Regenix to feature via Discovery Channel
uk.finance.yahoo.com - July 21 at 6:09 AM
morningstar.co.uk logoTissue Regenix Makes OrthoPure Progress In Europe And US
www.morningstar.co.uk - July 11 at 7:48 PM
uk.finance.yahoo.com logoTissue Regenix Appoints Orthopedic Clinical Advisory Board in the US
uk.finance.yahoo.com - July 5 at 9:24 AM

Social

Social activity is not available for this stock.

Chart

Tissue Regenix Group PLC (TRX) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by MarketBeat.com Staff